Antonius van Dijk - 09 Jan 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Chief Scientific Officer
Signature
By: /s/ Christine Klaskin, Attorney-in-Fact for Marcus Antonius van Dijk
Issuer symbol
INKT
Transactions as of
09 Jan 2023
Transactions value $
$0
Form type
4
Filing time
11 Jan 2023, 16:26:37 UTC
Previous filing
25 Jan 2022
Next filing
18 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option Award $0 +15,000 $0 15,000 09 Jan 2023 Common Stock 15,000 $2.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option was granted on January 9, 2023 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.